25 XP   0   0   10

Iteos Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Iteos Therapeutics Inc together

PenkeI guess you are interested in Iteos Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Iteos Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Iteos Therapeutics Inc

I send you an email if I find something interesting about Iteos Therapeutics Inc.

Quick analysis of Iteos Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Iteos Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$16.05
Expected worth in 1 year
$14.58
How sure are you?
52.9%

+ What do you gain per year?

Total Gains per Share
$-1.46
Return On Investment
-14.2%

For what price can you sell your share?

Current Price per Share
$10.33
Expected price per share
$9.85 - $16.48
How sure are you?
50%

1. Valuation of Iteos Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$10.33

Intrinsic Value Per Share

$6.82 - $7.09

Total Value Per Share

$22.87 - $23.14

2. Growth of Iteos Therapeutics Inc (5 min.)




Is Iteos Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$575.2m$640.3m-$27.9m-4.6%

How much money is Iteos Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$28.1m$24.1m-$52.3m-185.8%
Net Profit Margin-30.9%25.5%--

How much money comes from the company's main activities?

3. Financial Health of Iteos Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#92 / 1016

Most Revenue
#395 / 1016

Most Profit
#773 / 1016

Most Efficient
#517 / 1016

What can you expect buying and holding a share of Iteos Therapeutics Inc? (5 min.)

Welcome investor! Iteos Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Iteos Therapeutics Inc.

What can you expect buying and holding a share of Iteos Therapeutics Inc?

First you should know what it really means to hold a share of Iteos Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Iteos Therapeutics Inc is $10.33. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Iteos Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Iteos Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $16.05. Based on the TTM, the Book Value Change Per Share is $-0.37 per quarter. Based on the YOY, the Book Value Change Per Share is $0.69 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Iteos Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.85-8.3%-0.79-7.6%0.646.1%0.222.1%0.222.1%
Usd Book Value Change Per Share-0.64-6.2%-0.37-3.5%0.696.7%0.949.1%0.949.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.64-6.2%-0.37-3.5%0.696.7%0.949.1%0.949.1%
Usd Price Per Share10.95-12.19-22.84-19.53-19.53-
Price to Earnings Ratio-3.21--4.39-57.22-8.63-8.63-
Price-to-Total Gains Ratio-17.04--7.30--29.94--26.67--26.67-
Price to Book Ratio0.68-0.71-1.36-1.63-1.63-
Price-to-Total Gains Ratio-17.04--7.30--29.94--26.67--26.67-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share10.33
Number of shares96
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.370.94
Usd Total Gains Per Share-0.370.94
Gains per Quarter (96 shares)-35.1590.63
Gains per Year (96 shares)-140.62362.51
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-141-1510363353
20-281-2920725716
30-422-433010881079
40-562-574014501442
50-703-715018131805
60-844-856021752168
70-984-997025382531
80-1125-1138029002894
90-1266-1279032633257
100-1406-1420036253620

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%6.06.00.050.0%6.011.00.035.3%6.011.00.035.3%6.011.00.035.3%
Book Value Change Per Share1.03.00.025.0%6.06.00.050.0%9.08.00.052.9%9.08.00.052.9%9.08.00.052.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.017.00.0%0.00.017.00.0%0.00.017.00.0%
Total Gains per Share1.03.00.025.0%6.06.00.050.0%9.08.00.052.9%9.08.00.052.9%9.08.00.052.9%

Fundamentals of Iteos Therapeutics Inc

About Iteos Therapeutics Inc

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc"R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 12:19:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Iteos Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Iteos Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Iteos Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Iteos Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-30.9%+30.9%
TTM-30.9%YOY25.5%-56.4%
TTM-30.9%5Y7.2%-38.1%
5Y7.2%10Y7.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--199.6%+199.6%
TTM-30.9%-213.0%+182.1%
YOY25.5%-279.3%+304.8%
5Y7.2%-438.4%+445.6%
10Y7.2%-605.5%+612.7%
1.1.2. Return on Assets

Shows how efficient Iteos Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Iteos Therapeutics Inc to the Biotechnology industry mean.
  • -4.6% Return on Assets means that Iteos Therapeutics Inc generated $-0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Iteos Therapeutics Inc:

  • The MRQ is -4.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -4.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.6%TTM-4.1%-0.5%
TTM-4.1%YOY2.9%-7.0%
TTM-4.1%5Y-1.3%-2.8%
5Y-1.3%10Y-1.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.6%-13.5%+8.9%
TTM-4.1%-12.9%+8.8%
YOY2.9%-11.8%+14.7%
5Y-1.3%-14.1%+12.8%
10Y-1.3%-16.0%+14.7%
1.1.3. Return on Equity

Shows how efficient Iteos Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Iteos Therapeutics Inc to the Biotechnology industry mean.
  • -5.3% Return on Equity means Iteos Therapeutics Inc generated $-0.05 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Iteos Therapeutics Inc:

  • The MRQ is -5.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.3%TTM-4.6%-0.7%
TTM-4.6%YOY3.8%-8.5%
TTM-4.6%5Y-0.9%-3.7%
5Y-0.9%10Y-0.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.3%-16.9%+11.6%
TTM-4.6%-16.1%+11.5%
YOY3.8%-15.1%+18.9%
5Y-0.9%-19.9%+19.0%
10Y-0.9%-20.9%+20.0%

1.2. Operating Efficiency of Iteos Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Iteos Therapeutics Inc is operating .

  • Measures how much profit Iteos Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Iteos Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Iteos Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-49.5%+49.5%
TTM-49.5%YOY10.4%-59.8%
TTM-49.5%5Y0.6%-50.1%
5Y0.6%10Y0.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--295.1%+295.1%
TTM-49.5%-225.8%+176.3%
YOY10.4%-288.4%+298.8%
5Y0.6%-477.4%+478.0%
10Y0.6%-625.6%+626.2%
1.2.2. Operating Ratio

Measures how efficient Iteos Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Iteos Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.728-0.728
TTM0.728YOY0.882-0.154
TTM0.7285Y0.398+0.330
5Y0.39810Y0.3980.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.090-3.090
TTM0.7283.264-2.536
YOY0.8823.783-2.901
5Y0.3985.679-5.281
10Y0.3987.894-7.496

1.3. Liquidity of Iteos Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Iteos Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 13.76 means the company has $13.76 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Iteos Therapeutics Inc:

  • The MRQ is 13.761. The company is very able to pay all its short-term debts. +2
  • The TTM is 19.879. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ13.761TTM19.879-6.117
TTM19.879YOY8.598+11.281
TTM19.8795Y14.859+5.020
5Y14.85910Y14.8590.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.7613.914+9.847
TTM19.8794.220+15.659
YOY8.5985.388+3.210
5Y14.8596.045+8.814
10Y14.8596.406+8.453
1.3.2. Quick Ratio

Measures if Iteos Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Iteos Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 20.47 means the company can pay off $20.47 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Iteos Therapeutics Inc:

  • The MRQ is 20.472. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 31.479. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ20.472TTM31.479-11.007
TTM31.479YOY10.411+21.068
TTM31.4795Y17.926+13.553
5Y17.92610Y17.9260.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ20.4723.572+16.900
TTM31.4793.998+27.481
YOY10.4115.390+5.021
5Y17.9265.969+11.957
10Y17.9266.287+11.639

1.4. Solvency of Iteos Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Iteos Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Iteos Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.14 means that Iteos Therapeutics Inc assets are financed with 13.8% credit (debt) and the remaining percentage (100% - 13.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Iteos Therapeutics Inc:

  • The MRQ is 0.138. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.118. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.138TTM0.118+0.020
TTM0.118YOY0.197-0.078
TTM0.1185Y0.186-0.067
5Y0.18610Y0.1860.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1380.336-0.198
TTM0.1180.334-0.216
YOY0.1970.269-0.072
5Y0.1860.366-0.180
10Y0.1860.390-0.204
1.4.2. Debt to Equity Ratio

Measures if Iteos Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Iteos Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 16.1% means that company has $0.16 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Iteos Therapeutics Inc:

  • The MRQ is 0.161. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.135. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.161TTM0.135+0.026
TTM0.135YOY0.250-0.116
TTM0.1355Y0.297-0.163
5Y0.29710Y0.2970.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1610.382-0.221
TTM0.1350.396-0.261
YOY0.2500.335-0.085
5Y0.2970.434-0.137
10Y0.2970.465-0.168

2. Market Valuation of Iteos Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Iteos Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Iteos Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -3.21 means the investor is paying $-3.21 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Iteos Therapeutics Inc:

  • The EOD is -3.030. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.212. Based on the earnings, the company is expensive. -2
  • The TTM is -4.389. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.030MRQ-3.212+0.182
MRQ-3.212TTM-4.389+1.177
TTM-4.389YOY57.217-61.606
TTM-4.3895Y8.628-13.017
5Y8.62810Y8.6280.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.030-2.259-0.771
MRQ-3.212-2.569-0.643
TTM-4.389-2.664-1.725
YOY57.217-4.120+61.337
5Y8.628-6.258+14.886
10Y8.628-6.171+14.799
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Iteos Therapeutics Inc:

  • The EOD is -6.105. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.472. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.450. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.105MRQ-6.472+0.366
MRQ-6.472TTM-4.450-2.022
TTM-4.450YOY-7.937+3.487
TTM-4.4505Y-9.704+5.254
5Y-9.70410Y-9.7040.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.105-2.924-3.181
MRQ-6.472-3.246-3.226
TTM-4.450-3.488-0.962
YOY-7.937-5.620-2.317
5Y-9.704-8.315-1.389
10Y-9.704-8.826-0.878
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Iteos Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.68 means the investor is paying $0.68 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Iteos Therapeutics Inc:

  • The EOD is 0.644. Based on the equity, the company is cheap. +2
  • The MRQ is 0.682. Based on the equity, the company is cheap. +2
  • The TTM is 0.712. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.644MRQ0.682-0.039
MRQ0.682TTM0.712-0.030
TTM0.712YOY1.356-0.644
TTM0.7125Y1.625-0.913
5Y1.62510Y1.6250.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.6441.851-1.207
MRQ0.6822.090-1.408
TTM0.7122.095-1.383
YOY1.3562.844-1.488
5Y1.6253.466-1.841
10Y1.6253.815-2.190
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Iteos Therapeutics Inc.

3.1. Institutions holding Iteos Therapeutics Inc

Institutions are holding 102.364% of the shares of Iteos Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31RA Capital Management, LLC12.32560.7555441725900
2023-12-31BlackRock Inc11.89170.00124261745-789223-15.6252
2023-12-31Mpm Asset Management, LLC7.642114.7369273878500
2023-12-31Boxer Capital LLC5.03390.9846180405800
2023-12-31MPM Oncology Impact Management LP4.87184.4728174594300
2023-12-31Vanguard Group Inc4.16020.00041490942-322817-17.7982
2023-12-31Goldman Sachs Group Inc4.14120.00151484136874924143.6157
2023-09-30Bvf Inc3.51440.37191259476-551359-30.4478
2023-12-31Morgan Stanley - Brokerage Accounts3.15720.00111131493869740332.2751
2023-12-31EcoR1 Capital, LLC3.11130.317111502211150220
2023-09-30Citadel Advisors Llc2.81150.00241007572-187697-15.7033
2023-12-31Millennium Management LLC2.69940.0046967402-65444-6.3363
2023-12-31Saturn V Capital Management LLC2.3113.4715828232-166524-16.7402
2023-12-31Dimensional Fund Advisors, Inc.2.15730.00257731437219010.2988
2023-09-30Deerfield Management Co2.01740.17447230007230000
2023-12-31683 Capital Management LLC1.99510.6412715000-95000-11.7284
2023-12-31Renaissance Technologies Corp1.95020.011969890030490077.3858
2023-12-31Geode Capital Management, LLC1.58730.0007568860367736.9111
2023-12-31State Street Corporation1.5390.0003551555-1029938-65.1244
2023-09-30Jacobs Levy Equity Management, Inc.1.28270.0298459712-30668-6.2539
Total 80.200325.982228742235+757879+2.6%

3.2. Funds holding Iteos Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.15220.000577142000
2024-03-28iShares Russell 2000 ETF1.74550.0136256513030.0485
2024-02-29BlackRock Advantage Small Cap Core Instl1.13060.1237405245-22711-5.3069
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.0910.004139105200
2023-12-31Econopolis Belgian Champions A EUR Dis0.8373.496330000000
2024-01-31CREF Stock R10.73760.002226439013139098.7895
2024-01-31Fidelity Small Cap Index0.69330.0124849115270.6183
2024-03-28iShares Russell 2000 Value ETF0.64730.0252232008-147-0.0633
2024-03-28iShares Biotechnology ETF0.59280.038212468-5812-2.6626
2024-02-29DFA US Targeted Value I0.49630.014817789100
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.45530.004216320010000.6165
2024-02-29Fidelity Extended Market Index0.40780.0041146166-708-0.482
2024-01-31Goldman Sachs Small Cp Val Insghts Instl0.40070.164614364000
2024-03-31Blackrock Russell 2000 Alpha Tilts Fd A0.36420.186413053927952.188
2024-03-29Schwab US Small-Cap ETF™0.3490.0112510000
2024-03-29Dimensional US Targeted Value ETF0.29880.014510710000
2024-02-29PGIM Quant Solutions Small-Cap Val Z0.26670.25889560044004.8246
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.25950.0139301200
2024-02-29Vanguard Russell 2000 ETF0.24970.01018949771208.6432
2023-12-31PGIM Quant Small Cap value Equity0.24770.230388800-8800-9.0164
Total 13.4234.62384811270+110357+2.3%

3.3. Insider Transactions

Insiders are holding 0.542% of the shares of Iteos Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-10-12Matthew GallBUY50008.37
2023-08-23Boxer Capital, LlcSELL35000016.26

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Iteos Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.643-0.366-43%0.691-193%0.944-168%0.944-168%
Book Value Per Share--16.04917.083-6%16.928-5%11.996+34%11.996+34%
Current Ratio--13.76119.879-31%8.598+60%14.859-7%14.859-7%
Debt To Asset Ratio--0.1380.118+17%0.197-30%0.186-26%0.186-26%
Debt To Equity Ratio--0.1610.135+19%0.250-36%0.297-46%0.297-46%
Dividend Per Share----0%-0%-0%-0%
Eps---0.852-0.786-8%0.635-234%0.218-490%0.218-490%
Free Cash Flow Per Share---0.423-0.744+76%-0.741+75%0.398-206%0.398-206%
Free Cash Flow To Equity Per Share---0.414-0.737+78%-0.728+76%0.967-143%0.967-143%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--7.094--------
Intrinsic Value_10Y_min--6.821--------
Intrinsic Value_1Y_max--2.294--------
Intrinsic Value_1Y_min--2.254--------
Intrinsic Value_3Y_max--5.686--------
Intrinsic Value_3Y_min--5.453--------
Intrinsic Value_5Y_max--7.623--------
Intrinsic Value_5Y_min--7.180--------
Market Cap370259223.000-6%392481945.000436837781.250-10%864892953.828-55%717944764.656-45%717944764.656-45%
Net Profit Margin----0.3090%0.255-100%0.072-100%0.072-100%
Operating Margin----0.4950%0.104-100%0.006-100%0.006-100%
Operating Ratio---0.728-100%0.882-100%0.398-100%0.398-100%
Pb Ratio0.644-6%0.6820.712-4%1.356-50%1.625-58%1.625-58%
Pe Ratio-3.030+6%-3.212-4.389+37%57.217-106%8.628-137%8.628-137%
Price Per Share10.330-6%10.95012.188-10%22.840-52%19.529-44%19.529-44%
Price To Free Cash Flow Ratio-6.105+6%-6.472-4.450-31%-7.937+23%-9.704+50%-9.704+50%
Price To Total Gains Ratio-16.074+6%-17.039-7.301-57%-29.943+76%-26.670+57%-26.670+57%
Quick Ratio--20.47231.479-35%10.411+97%17.926+14%17.926+14%
Return On Assets---0.046-0.041-11%0.029-256%-0.013-72%-0.013-72%
Return On Equity---0.053-0.046-13%0.038-239%-0.009-82%-0.009-82%
Total Gains Per Share---0.643-0.366-43%0.691-193%0.944-168%0.944-168%
Usd Book Value--575228000.000612319500.000-6%640302500.000-10%440261647.059+31%440261647.059+31%
Usd Book Value Change Per Share---0.643-0.366-43%0.691-193%0.944-168%0.944-168%
Usd Book Value Per Share--16.04917.083-6%16.928-5%11.996+34%11.996+34%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.852-0.786-8%0.635-234%0.218-490%0.218-490%
Usd Free Cash Flow---15161000.000-26680500.000+76%-28032750.000+85%15332176.471-199%15332176.471-199%
Usd Free Cash Flow Per Share---0.423-0.744+76%-0.741+75%0.398-206%0.398-206%
Usd Free Cash Flow To Equity Per Share---0.414-0.737+78%-0.728+76%0.967-143%0.967-143%
Usd Market Cap370259223.000-6%392481945.000436837781.250-10%864892953.828-55%717944764.656-45%717944764.656-45%
Usd Price Per Share10.330-6%10.95012.188-10%22.840-52%19.529-44%19.529-44%
Usd Profit---30551000.000-28160750.000-8%24163000.000-226%9124764.706-435%9124764.706-435%
Usd Revenue---3148750.000-100%66907500.000-100%36764705.882-100%36764705.882-100%
Usd Total Gains Per Share---0.643-0.366-43%0.691-193%0.944-168%0.944-168%
 EOD+3 -5MRQTTM+9 -22YOY+14 -195Y+11 -2210Y+11 -22

4.2. Fundamental Score

Let's check the fundamental score of Iteos Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.030
Price to Book Ratio (EOD)Between0-10.644
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than120.472
Current Ratio (MRQ)Greater than113.761
Debt to Asset Ratio (MRQ)Less than10.138
Debt to Equity Ratio (MRQ)Less than10.161
Return on Equity (MRQ)Greater than0.15-0.053
Return on Assets (MRQ)Greater than0.05-0.046
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Iteos Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.608
Ma 20Greater thanMa 5012.102
Ma 50Greater thanMa 10011.336
Ma 100Greater thanMa 20010.914
OpenGreater thanClose10.620
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets667,588
Total Liabilities92,360
Total Stockholder Equity575,228
 As reported
Total Liabilities 92,360
Total Stockholder Equity+ 575,228
Total Assets = 667,588

Assets

Total Assets667,588
Total Current Assets550,652
Long-term Assets116,936
Total Current Assets
Cash And Cash Equivalents 251,177
Short-term Investments 280,739
Net Receivables 6,500
Other Current Assets 12,236
Total Current Assets  (as reported)550,652
Total Current Assets  (calculated)550,652
+/-0
Long-term Assets
Property Plant Equipment 10,732
Long Term Investments 100,539
Long-term Assets Other 5,665
Long-term Assets  (as reported)116,936
Long-term Assets  (calculated)116,936
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities40,014
Long-term Liabilities52,346
Total Stockholder Equity575,228
Total Current Liabilities
Short-term Debt 1,251
Accounts payable 11,293
Other Current Liabilities 25,407
Total Current Liabilities  (as reported)40,014
Total Current Liabilities  (calculated)37,951
+/- 2,063
Long-term Liabilities
Capital Lease Obligations 6,058
Long-term Liabilities  (as reported)52,346
Long-term Liabilities  (calculated)6,058
+/- 46,288
Total Stockholder Equity
Common Stock36
Retained Earnings 124,633
Accumulated Other Comprehensive Income -13,240
Other Stockholders Equity 463,799
Total Stockholder Equity (as reported)575,228
Total Stockholder Equity (calculated)575,228
+/-0
Other
Capital Stock36
Cash and Short Term Investments 531,916
Common Stock Shares Outstanding 35,838
Current Deferred Revenue2,063
Liabilities and Stockholders Equity 667,588
Net Debt -245,119
Net Invested Capital 575,228
Net Working Capital 510,638
Property Plant and Equipment Gross 15,114
Short Long Term Debt Total 6,058



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
0
0
0
30,744
153,970
145,211
350,944
344,558
332,889
318,685
922,379
884,712
850,321
814,774
777,873
754,991
728,346
703,746
677,644
667,588
667,588677,644703,746728,346754,991777,873814,774850,321884,712922,379318,685332,889344,558350,944145,211153,97030,744000
   > Total Current Assets 
0
0
0
26,076
149,271
140,395
345,734
339,544
324,919
309,768
914,137
874,713
840,660
804,743
768,546
628,298
615,401
614,547
619,128
550,652
550,652619,128614,547615,401628,298768,546804,743840,660874,713914,137309,768324,919339,544345,734140,395149,27126,076000
       Cash And Cash Equivalents 
0
0
0
19,868
147,732
136,870
339,981
336,326
321,385
302,933
899,767
848,537
823,984
791,861
752,243
284,803
225,361
216,213
204,134
251,177
251,177204,134216,213225,361284,803752,243791,861823,984848,537899,767302,933321,385336,326339,981136,870147,73219,868000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
328,359
376,776
383,011
394,893
280,739
280,739394,893383,011376,776328,359000000000000000
       Net Receivables 
0
0
0
5,329
233
345
2,491
325
1,241
4,232
5,430
12,090
4,619
4,004
4,563
2,435
668
3,683
6,312
6,500
6,5006,3123,6836682,4354,5634,0044,61912,0905,4304,2321,2413252,4913452335,329000
       Other Current Assets 
0
0
0
879
1,306
3,180
3,262
2,893
2,293
2,603
8,940
26,176
12,057
8,878
11,740
12,701
12,596
11,640
13,789
12,236
12,23613,78911,64012,59612,70111,7408,87812,05726,1768,9402,6032,2932,8933,2623,1801,306879000
   > Long-term Assets 
0
0
0
4,668
4,699
4,816
5,210
5,014
7,970
8,917
8,242
9,999
9,661
10,031
9,327
126,693
112,945
89,200
58,516
116,936
116,93658,51689,200112,945126,6939,32710,0319,6619,9998,2428,9177,9705,0145,2104,8164,6994,668000
       Property Plant Equipment 
0
0
0
1,336
1,244
1,251
1,287
1,352
4,396
5,069
4,980
7,401
7,450
7,063
6,576
6,773
6,721
7,976
9,243
10,732
10,7329,2437,9766,7216,7736,5767,0637,4507,4014,9805,0694,3961,3521,2871,2511,2441,336000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
118,225
104,484
78,260
45,897
100,539
100,53945,89778,260104,484118,225000000000000000
       Other Assets 
0
0
0
0
3,455
3,565
3,923
3,662
3,574
3,848
3,262
2,598
2,211
2,968
2,751
1,695
0
-1
0
0
00-101,6952,7512,9682,2112,5983,2623,8483,5743,6623,9233,5653,4550000
> Total Liabilities 
0
0
0
15,075
14,518
12,161
15,318
21,361
20,280
29,187
550,340
331,892
223,943
177,473
143,674
91,659
76,084
80,220
79,382
92,360
92,36079,38280,22076,08491,659143,674177,473223,943331,892550,34029,18720,28021,36115,31812,16114,51815,075000
   > Total Current Liabilities 
0
0
0
13,196
9,973
7,516
10,325
14,998
11,830
20,763
542,228
304,124
174,253
125,395
93,831
42,000
26,358
30,023
28,223
40,014
40,01428,22330,02326,35842,00093,831125,395174,253304,124542,22820,76311,83014,99810,3257,5169,97313,196000
       Short-term Debt 
0
0
0
4,262
0
0
0
0
550
555
486
770
786
778
767
836
864
1,021
1,117
1,251
1,2511,1171,02186483676777878677048655555000004,262000
       Accounts payable 
0
0
0
1,174
4,511
2,656
2,409
3,026
5,300
11,661
4,707
5,145
10,603
10,921
9,603
7,662
5,694
5,227
3,419
11,293
11,2933,4195,2275,6947,6629,60310,92110,6035,1454,70711,6615,3003,0262,4092,6564,5111,174000
       Other Current Liabilities 
0
0
0
5,400
3,221
3,360
6,054
7,486
5,314
7,570
14,960
17,157
34,159
26,771
15,976
19,727
17,727
21,247
22,049
25,407
25,40722,04921,24717,72719,72715,97626,77134,15917,15714,9607,5705,3147,4866,0543,3603,2215,400000
   > Long-term Liabilities 
0
0
0
1,879
4,545
4,645
4,993
6,363
8,450
8,424
8,112
27,768
49,690
52,078
49,843
49,659
49,726
50,197
51,159
52,346
52,34651,15950,19749,72649,65949,84352,07849,69027,7688,1128,4248,4506,3634,9934,6454,5451,879000
       Other Liabilities 
0
0
0
0
4,545
4,645
4,993
6,363
5,947
5,923
5,729
23,197
45,229
48,049
46,115
45,822
0
45,770
0
0
0045,770045,82246,11548,04945,22923,1975,7295,9235,9476,3634,9934,6454,5450000
> Total Stockholder Equity
0
0
0
15,669
139,452
133,050
335,626
323,197
312,609
289,498
372,039
552,820
626,378
637,301
634,199
663,332
652,262
623,526
598,262
575,228
575,228598,262623,526652,262663,332634,199637,301626,378552,820372,039289,498312,609323,197335,626133,050139,45215,669000
   Common Stock
0
0
0
1
22
1
35
35
35
35
35
35
36
36
36
36
36
36
36
36
36363636363636363535353535351221000
   Retained Earnings Total Equity
0
0
0
0
0
0
0
-73,898
-87,432
-113,891
-44,249
140,623
210,205
215,831
216,822
237,275
221,724
0
0
0
000221,724237,275216,822215,831210,205140,623-44,249-113,891-87,432-73,8980000000
   Accumulated Other Comprehensive Income 
0
0
0
-224
-541
-296
97
617
312
238
8,754
-1,018
-1,568
-2,309
-12,125
-9,644
-11,548
-13,166
-13,256
-13,240
-13,240-13,256-13,166-11,548-9,644-12,125-2,309-1,568-1,0188,75423831261797-296-541-224000
   Capital Surplus 
0
0
0
0
3,126
0
0
396,443
399,694
403,116
407,499
413,180
417,705
423,743
429,466
435,665
442,050
0
0
0
000442,050435,665429,466423,743417,705413,180407,499403,116399,694396,443003,1260000
   Treasury Stock00000000000000000000
   Other Stockholders Equity 
0
0
0
0
181,083
687
43,544
396,443
66,805
84,431
407,499
413,180
417,705
423,743
429,466
435,665
442,050
449,232
456,299
463,799
463,799456,299449,232442,050435,665429,466423,743417,705413,180407,49984,43166,805396,44343,544687181,0830000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue12,595
Cost of Revenue-898
Gross Profit11,69711,697
 
Operating Income (+$)
Gross Profit11,697
Operating Expense-157,482
Operating Income-151,101-145,785
 
Operating Expense (+$)
Research Development113,300
Selling General Administrative50,396
Selling And Marketing Expenses0
Operating Expense157,482163,696
 
Net Interest Income (+$)
Interest Income30,900
Interest Expense-0
Other Finance Cost-0
Net Interest Income30,900
 
Pretax Income (+$)
Operating Income-151,101
Net Interest Income30,900
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-109,030-155,184
EBIT - interestExpense = -144,887
-109,030
-112,642
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-144,887-109,030
Earnings Before Interest and Taxes (EBITDA)-143,989
 
After tax Income (+$)
Income Before Tax-109,030
Tax Provision-3,542
Net Income From Continuing Ops-61,638-112,572
Net Income-112,642
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses157,482
Total Other Income/Expenses Net4,083-30,900
 

Technical Analysis of Iteos Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Iteos Therapeutics Inc. The general trend of Iteos Therapeutics Inc is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Iteos Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Iteos Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 13.35 < 13.80 < 16.48.

The bearish price targets are: 10.20 > 9.88 > 9.85.

Tweet this
Iteos Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Iteos Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Iteos Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Iteos Therapeutics Inc. The current macd is -0.1110281.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Iteos Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Iteos Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Iteos Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Iteos Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartIteos Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Iteos Therapeutics Inc. The current adx is 19.11.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Iteos Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Iteos Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Iteos Therapeutics Inc. The current sar is 13.18.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Iteos Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Iteos Therapeutics Inc. The current rsi is 36.61. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Iteos Therapeutics Inc Daily Relative Strength Index (RSI) ChartIteos Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Iteos Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Iteos Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Iteos Therapeutics Inc Daily Stochastic Oscillator ChartIteos Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Iteos Therapeutics Inc. The current cci is -166.76025147.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Iteos Therapeutics Inc Daily Commodity Channel Index (CCI) ChartIteos Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Iteos Therapeutics Inc. The current cmo is -43.99148806.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Iteos Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartIteos Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Iteos Therapeutics Inc. The current willr is -97.47191011.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Iteos Therapeutics Inc Daily Williams %R ChartIteos Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Iteos Therapeutics Inc.

Iteos Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Iteos Therapeutics Inc. The current atr is 0.62451114.

Iteos Therapeutics Inc Daily Average True Range (ATR) ChartIteos Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Iteos Therapeutics Inc. The current obv is 16,616,547.

Iteos Therapeutics Inc Daily On-Balance Volume (OBV) ChartIteos Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Iteos Therapeutics Inc. The current mfi is 45.23.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Iteos Therapeutics Inc Daily Money Flow Index (MFI) ChartIteos Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Iteos Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-29MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-27BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-01RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.

6.3. Candlestick Patterns

Iteos Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Iteos Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.608
Ma 20Greater thanMa 5012.102
Ma 50Greater thanMa 10011.336
Ma 100Greater thanMa 20010.914
OpenGreater thanClose10.620
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Iteos Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Iteos Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Iteos Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Iteos Therapeutics Inc

I send you an email if I find something interesting about Iteos Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Iteos Therapeutics Inc.

Receive notifications about Iteos Therapeutics Inc in your mailbox!